ESMO 2024 | Do chemotherapy-free approaches have a role in HER2+ early breast cancer?
Oleg Gluz, MD, Evang. Krankenhaus “”Bethesda”” Klinik, Mönchengladbach, Germany, comments ongoing research into chemotherapy-free treatment approaches for patients with HER2+ breast cancer. Key trials such as PHERGain-2 (NCT04595565), ATEMPT (NCT01853748), and WSG TP-II (NCT03272477) examine HER2 blockade and endocrine therapy as alternatives to chemotherapy in early-stage, node-negative disease. However, more data are needed to determine the safety and efficacy of these regimens, especially in smaller tumors and older patients. This interview took place at the European Society for Medical Oncology (ESMO) 2024 Congress in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
